null Dick Menzies, MD

Senior Scientist, RI-MUHC, 5252 de Maisonneuve site

Translational Research in Respiratory Diseases Program

Centre for Outcomes Research and Evaluation

Professor, Department of Medicine, Faculty of Medicine and Health Sciences, McGill University

Department of Medicine, Division of Respiratory Medicine, MUHC



tuberculosis • biostatistics • epidemiology • respiratory disease • global health

Research Focus

My research involves clinical and epidemiologic studies of the diagnosis and treatment of tuberculosis (TB). This includes latent (dormant) TB and active TB (disease), as well as drug-sensitive and drug-resistant TB. My international reseach collaborations include work in sites in Benin, West Africa, Brazil, Indonesia and Vietnam. Within Canada, I am part of a network of TB researchers in Ottawa, Toronto, Calagary, Edmonton and Vancouver.

Selected Publications

Click on Pubmed to see my current publications list

  • Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, Obeng Baah J, Marks GB, Long R, Hoeppner V, Elwood K, Al-Jahdali H, Gninafon M, Apriani L, Koesoemadinata RC, Kritski A, Rolla V, Bah B, Camara A, Boakye I, Cook VJ, Goldberg H, Valiquette C, Hornby K, Dion MJ, Li PZ, Hill PC, Schwartzman K, Benedetti A. “Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults”. N Engl J Med. 2018 Aug 2;379:440-53. doi: 10.1056/NEJMoa1714283. PMID: 30067931.

  • Diallo T, Adjobimey M, Ruslami R, Trajman A, Sow O, Obeng Baah J, Marks GB, Long R, Elwood K, Zielinski D, Gninafon M, Wulandari DA, Apriani L, Valiquette C, Fregonese F, Hornby K, Li PZ, Hill PC, Schwartzman K, Benedetti A, Menzies D. “Safety and Side Effects of Rifampin versus Isoniazid in Children”. N Engl J Med. 2018 Aug 2;379:454-63. doi: 10.1056/NEJMoa1714284. PMID: 30067928.

  • Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, Baghaei P, Bang D, Barry PM, Bastos ML, Behera D, Benedetti A, Bisson GP, Boeree MJ, Bonnet M, Brode SK, Brust JCM, Cai Y, Caumes E, Cegielski JP, Centis R, Chan PC, Chan ED, Chang KC, Charles M, Cirule A, Dalcolmo MP, D'Ambrosio L, de Vries G, Dheda K, Esmail A, Flood J, Fox GJ, Fréchet-Jachym M, Fregona G, Gayoso R, Gegia M, Gler MT, Gu S, Guglielmetti L, Holtz TH, Hughes J, Isaakidis P, Jarlsberg L, Kempker RR, Keshavjee S, Khan FA, Kipiani M, Koenig SP, Koh WJ, Kritski A, Kuksa L, Kvasnovsky CL, Kwak N, Lan Z, Lange C, Laniado-Laborín R, Lee M, Leimane V, Leung CC, Leung EC, Li PZ, Lowenthal P, Maciel EL, Marks SM, Mase S, Mbuagbaw L, Migliori GB, Milanov V, Miller AC, Mitnick CD, Modongo C, Mohr E, Monedero I, Nahid P, Ndjeka N, O'Donnell MR, Padayatchi N, Palmero D, Pape JW, Podewils LJ.... Menzies D; Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017. “Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis”. Lancet. 2018 Sep 8;392(10150): 821-834. doi: 10.1016/S0140-6736(18)31644-1. PMID: 30215381.

  • Bastos ML, Campbell JR, Oxlade O, Adjobimey M, Trajman A, Ruslami R, Kim HJ, Obeng J, Toelle BG, Long R, Hoeppner V, Elwood K, Al-Jahdali H, Apriani L, Benedetti A, Schwartzman K, Menzies D.“Health System Costs of Treating Latent Tuberculosis Infection With Four Months of Rifampin Versus Nine Months of Isoniazid in Different Settings.” Annals of Internal Medicine. 2020 Aug 4;173(3):169-178. doi: 10.7326/M19-3741. PMID: 32539440.

  • Campbell JR, Winters N, Menzies D. “Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-gamma release assay result: systematic review and meta-analysis.” BMJ. 2020 Mar 10;368:m549. doi: 10.1136/bmj.m549. PMID: 32156698.